SCHEMBL13726541

SCHEMBL13726541

c1ccc(-c2nc3ccccc3nc2-c2ccc3c(c2)C2(c4ccccc4-c4ccccc42)c2cc(-c4cccnc4)ccc2-3)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDK2 Q15119 1/20 0.53
CYP11B1 P15538 5/20 0.43
CYP11B2 P19099 4/20 0.43
CYP19A1 P11511 3/20 0.43
CYP17A1 P05093 1/20 0.43
ALDH1A1 P00352 2/20 0.41
KDM4E B2RXH2 2/20 0.41
GAA P10253 2/20 0.41
MAPT P10636 1/20 0.41
DHODH Q02127 1/20 0.41
CYP2A6 P11509 1/20 0.41
TDP2 O95551 1/20 0.40
L3MBTL1 Q9Y468 3/20 0.40
LMNA P02545 2/20 0.39
THRB P10828 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
NAMPT P43490 1/20 0.38
AKT1 P31749 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13726054 0.99 PDK2 (0.52) PDK2CYP11B1CYP11B2CYP19A1CYP17A1
SCHEMBL13726813 0.98 PDK2 (0.53) PDK2CYP11B1CYP11B2CYP19A1CYP17A1
SCHEMBL13728260 0.97 PDK2 (0.55) PDK2CYP11B1CYP11B2CYP19A1CYP17A1
SCHEMBL13726910 0.96 PDK2 (0.54) PDK2CYP11B1CYP11B2CYP19A1CYP17A1
SCHEMBL13726657 0.96 PDK2 (0.51) PDK2CYP11B1CYP11B2CYP19A1CYP17A1
SCHEMBL13727937 0.96 PDK2 (0.54) PDK2CYP11B1CYP11B2CYP19A1CYP17A1
SCHEMBL13727084 0.92 PDK2 (0.47) PDK2CYP11B1CYP11B2CYP19A1CYP17A1
SCHEMBL24433148 0.91 PDK2 (0.47) PDK2CYP11B1CYP11B2CYP19A1CYP17A1
SCHEMBL13727380 0.90 PDK2 (0.50) PDK2CYP11B1CYP11B2CYP19A1CYP17A1
SCHEMBL13726308 0.90 PDK2 (0.47) PDK2CYP11B1CYP11B2CYP19A1CYP17A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2065378-B1 Quinoxaline derivate, and light-emitting element, light-emitting device, and electronic device using quinoxaline derivative SEMICONDUCTOR ENERGY LAB (JP) 2015-01-28 EP disclosed
US-8586740-B2 Quinoxaline derivative, and light-emitting element, light-emitting device, and electronic device using quinoxaline derivative SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2013-11-19 US disclosed
US-20130049577-A1 Quinoxaline Derivative, and Light-Emitting Element, Light-Emitting Device, and Electronic Device Using Quinoxaline Derivative SEMICONDUCTOR ENERGY LABORATORY CO., LTD. 2013-02-28 US disclosed
US-20130049577-A1 Quinoxaline Derivative, and Light-Emitting Element, Light-Emitting Device, and Electronic Device Using Quinoxaline Derivative SEMICONDUCTOR ENERGY LABORATORY CO., LTD. 2013-02-28 US disclosed
US-8314101-B2 Quinoxaline derivative, and light-emitting element, light-emitting device, and electronic device using quinoxaline derivative SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2012-11-20 US disclosed
US-20090203704-A1 Quinoxaline Derivative, and Light-Emitting Element, Light-Emitting Device, and Electronic Device Using Quinoxaline Derivative SEMICONDUCTOR ENERGY LABORATORY CO., LTD. 2009-08-13 US disclosed
US-20090203704-A1 Quinoxaline Derivative, and Light-Emitting Element, Light-Emitting Device, and Electronic Device Using Quinoxaline Derivative SEMICONDUCTOR ENERGY LABORATORY CO., LTD. 2009-08-13 US disclosed
EP-2065378-A1 Quinoxaline derivate, and light-emitting element, light-emitting device, and electronic device using quinoxaline derivative Semiconductor Energy Laboratory Co, Ltd. (JP) 2009-06-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090203704-A1 Quinoxaline Derivative, and Light-Emitting Element, Light-Emitting Device, and Electronic Device Using Quinoxaline Derivative PDXK, NQO1, PPOX PDK2 59/4885CYP11B1 2804/4885CYP11B2 1714/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.